Connect with us

Headlines

Sight Sciences Completes $30M Financing Round

It’s working on technology for glaucoma and dry eye disease.

mm

Published

on

MENLO PARK, CA — Sight Sciences Inc., a medical device company working on technology for treatment of glaucoma and dry eye disease, announced the closing of an over $30 million financing round.

Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences’ OMNI and TearCare products, according to a press release. The Series E preferred stock round was led by D1 Capital Partners.

Podcast: Talking with the Finest, Hippest of Them All About Why There are No Ball Point Pens in Her Shop
INVISION Podcast

Podcast: Talking with the Finest, Hippest of Them All About Why There are No Ball Point Pens in Her Shop

Licensed or Not, Member or Not, the Opticians Association of America is Here for You [Podcast]
INVISION Podcast

Licensed or Not, Member or Not, the Opticians Association of America is Here for You [Podcast]

Drs. Adam Ramsey and Darryl Glover Talk About Fostering Relationships Between Black ECPs and the Industry at Large
INVISION Podcast

Drs. Adam Ramsey and Darryl Glover Talk About Fostering Relationships Between Black ECPs and the Industry at Large

“Sight Sciences has introduced two technologies that have fundamentally improved how physicians can treat two of the most prevalent eye diseases. In minimally invasive glaucoma surgery the safety, efficacy and versatility of the OMNI device is unmatched,” said  James Rogers, analyst at D1 Capital Partners. “Additionally, we feel the early success with the commercialization of TearCare suggests this innovative and effective solution has addressed the shortfalls of previous dry eye treatments and modalities for this common ailment.”

Glaucoma affects 80 million people globally and is the leading cause of irreversible blindness in the aging world population. Dry eye disease afflicts 350 million people globally and is the leading cause of visits to an eyecare provider.

“We are thrilled to be closing a significant growth investment round with D1,” said Jesse Selnick, CFO of Sight Sciences. “D1 is truly a perfect fit for our company at this stage, combining the scale, market reach, investment talent and operational acumen of a large, premier asset manager with the flexible mandate and long-term investment horizon of a family office.”

Advertisement

Founded by Daniel Sundheim in 2018, D1 currently has $10 billion of capital under management and invests in the global internet, technology, telecom, media, consumer, healthcare, industrial and real estate sectors. Sight Sciences represents the third late-stage private healthcare investment made by D1 in the last 18 months.

“We are extremely excited to partner with D1 over the long term,” said Paul Badawi, founder and CEO of Sight Sciences. “This investment further validates the substantial progress we have made in our mission to transform the treatment of the world’s most prevalent eye diseases.  Through further clinical trials and continued scale-up of our commercial infrastructure, we are looking forward to accelerating the market development of both standalone MIGS with OMNI and procedure-based dry eye therapy with TearCare.”

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at [email protected].

Advertisement

SPONSORED VIDEO

SPONSORED BY ESSILOR

Introducing EssilorLuxottica 360

A new program powered by Essilor, Luxottica and EyeMed that is designed to help your practice improve traffic, visibility and patient experience while maximizing profitability. Learn More at 360.EssilorLuxottica.com

Promoted Headlines

Advertisement

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Facebook

Most Popular